Prescient Therapeutics (PTX) will progress to the next dose level of its Phase 1b clinical study of PTX-200 and cytarabine in patients with acute myeloid…

Melbourne biotech company Prescient Therapeutics (ASX:PTX) says a clinical trial evaluating its PTX-200 drug candidate to treat bone marrow is progressing to a higher dose. Three of…

The market for revolutionary CAR-T cancer treatments is expected to grow to USD 14 billion by 2030, according to new research. Figures published by research…

CAR-T Cell Immunotherapy Market Segmentation by Key Companies, Key Regions, Types and Application segmentation – History and Global Forecast 2021-2027 A comprehensive study of the…

When JVC launched VHS videos in 1971, it started a consumer revolution that permanently altered the way the public consume media. But in the 44…

We can readily understand why investors are attracted to unprofitable companies. For example, Prescient Therapeutics (ASX:PTX) shareholders have done very well over the last year, with the…

Two ASX-listed ventures are among the companies now investing billions of dollars to develop an emerging immunotherapy treatment known as CAR-T. From the upcoming Innovation…

The burgeoning CAR T therapy industry has passed another significant milestone after the US Food and Drug Administration (FDA) approved Breyanzi for use in certain…

Australian listed biotech company Prescient Therapeutics (ASX: PTX) is forging a path for other prospective cancer treatments, by developing a platform to improve the performance…

StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses cancer…